-
DaVinci Single Port System Launches in Hainan with Successful Surgeries
•
The DaVinci Single Port robot-assisted surgical system technology has been successfully implemented in Boao, Hainan province, marking a significant milestone for minimally invasive surgery in the region. Physicians from Ruijin Hospital have successfully carried out two urology procedures and one nasopharyngeal surgery using the advanced system. First Real-World Study and…
-
Shanghai’s SMPA Reduces Ceiling Price for Non-Winning Bids in Artificial Joint VBP Tender
•
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has issued a notification regarding an artificial joint volume-based procurement (VBP) tender, announcing a reduction in the ceiling price for non-winning bids to RMB 11,900 (USD 1,658). This move allows medical institutions to file online for non-winning products with prices above the new ceiling.…
-
Kunshan Yiyuan Medical Technology Secures Over RMB 100 Million in Series B Financing
•
Kunshan Yiyuan Medical Technology Co., Ltd (Medical Source), a company in China that specializes in the development of disruptive CT tubes, has reportedly raised over RMB 100 million in a Series B financing round. The round was led by Everest Venture Capital, with participation from Gaotou Venture Capital and Riverhead…
-
HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max
•
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm Kactus Biosystems, a company specializing in target protein and raw enzyme production. The agreement pertains to the new gene editing tool enzyme, hfCas12Max. According to the terms, Kactus will secure an exclusive license to produce…
-
Novartis China’s Business Growth Lead Zhu Jiakang Departs for Personal Reasons
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has seen the departure of Zhu Jiakang, who led the company’s innovative medicine China business growth project. Zhu has left the role due to “personal reasons,” according to official statements. Before joining Novartis in July 2022, Zhu held a significant position at AstraZeneca (AZ,…
-
BeiGene’s Q2 2023 Financial Report Highlights 81.8% YOY Product Revenue Growth
•
China-based biotech company BeiGene (SHA: 688235, HKG: 6160, NASDAQ: BGNE) has released its financial report for the second quarter of 2023, demonstrating strong year-on-year (YOY) growth of 81.8% in product revenues, reaching USD 553.7 million. Sales in China contributed USD 233.9 million, while the US market generated USD 223.5 million.…
-
National Health Commission’s Anti-Corruption Drive Impacts China’s Pharmaceutical Sector
•
An anti-corruption crackdown announced by the National Health Commission (NHC) at the end of July has quickly begun to impact the healthcare industry. Unlike previous efforts led by local authorities, this campaign is being driven by central authorities, with the Commission for Discipline Inspection of the Central Committee of the…
-
Our United Corporation’s Linear Accelerator Approved as Innovative Medical Device by NMPA
•
Xi’an-based Our United Corporation has announced that its medical electronic linear accelerator has been approved by the National Medical Products Administration (NMPA) as an innovative medical device. This marks a significant milestone for the company and the field of radiation therapy in China. Comprehensive Features of the Linear AcceleratorThe product,…
